Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG10

—

e5567926-5bc4-5076-a246-ec8dc11354c9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TGF_BETA_SIGNALING+0.305
  • MYOGENESIS+0.241
  • APICAL_JUNCTION+0.223
  • COAGULATION+0.199
  • APICAL_SURFACE+0.198
  • ESTROGEN_RESPONSE_EARLY+0.198
  • MITOTIC_SPINDLE+0.178
  • KRAS_SIGNALING_DN+0.168
  • UV_RESPONSE_DN+0.153
  • ANGIOGENESIS+0.146

Top 10 suppressed

  • E2F_TARGETS-0.423
  • G2M_CHECKPOINT-0.341
  • MYC_TARGETS_V2-0.335
  • OXIDATIVE_PHOSPHORYLATION-0.319
  • MYC_TARGETS_V1-0.302
  • ALLOGRAFT_REJECTION-0.254
  • MTORC1_SIGNALING-0.242
  • IL6_JAK_STAT3_SIGNALING-0.229
  • UNFOLDED_PROTEIN_RESPONSE-0.170
  • INTERFERON_GAMMA_RESPONSE-0.166

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG356
mng-umap@100
——0.829
2MNG438
mng-umap@100
——0.821
3TCGA-56-7822-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.812
4MNG117
mng-umap@100
——0.805
5s0095156
melanoma-umap@29
——0.778
6MNG905
mng-umap@100
——0.773
720030071.Her2HRpos
breast-umap@18
—A0.770
8TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.755
9MBCProject_2289_T2_RNA
breast-umap@18
—A0.755
10MNG359
mng-umap@100
——0.751

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TGF_BETA_SIGNALING0.305Inavolisib— uncovered
MYOGENESIS0.241Inavolisib— uncovered
APICAL_JUNCTION0.223Inavolisib— uncovered
COAGULATION0.199Binimetinib— uncovered
APICAL_SURFACE0.198Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.198Inavolisib— uncovered
MITOTIC_SPINDLE0.178Inavolisib— uncovered
KRAS_SIGNALING_DN0.168Remibrutinib— uncovered
UV_RESPONSE_DN0.153Inavolisib— uncovered
ANGIOGENESIS0.146Remibrutinib— uncovered
HYPOXIA0.124Idelalisib— uncovered
PEROXISOME0.123Idelalisib— uncovered
HEME_METABOLISM0.121Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.118Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.104Inavolisib— uncovered
ANDROGEN_RESPONSE0.082Inavolisib— uncovered
NOTCH_SIGNALING0.080Inavolisib— uncovered
APOPTOSIS0.073Idelalisib— uncovered
ADIPOGENESIS0.067Inavolisib— uncovered
BILE_ACID_METABOLISM0.061Inavolisib— uncovered